Company Overview - Huajian Medical Holdings Limited was established on January 15, 2016, under the laws of the Cayman Islands, primarily engaged in investment holding [3] - The company operates three subsidiaries in Hong Kong, focusing on research, production, and sales of in vitro diagnostic medical instruments and consumables, with a workforce of over 700 employees [3] - Huajian Medical has become a leading professional company in the in vitro diagnostic industry in China, providing valuable products and services to the testing sector [3] Financial Performance - As of December 31, 2024, Huajian Medical achieved total revenue of 3.162 billion yuan, representing a year-on-year growth of 2.4% [2] - The net profit attributable to the parent company was 260 million yuan, with a year-on-year increase of 9.35% [2] - The gross profit margin stood at 23.75%, and the debt-to-asset ratio was 31.91% [2] Stock Performance - As of August 6, the stock price of Huajian Medical closed at 7.96 HKD per share, marking an increase of 38.43% with a trading volume of 8.6666 million shares and a turnover of 57.6121 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 179.13%, and a year-to-date increase of 219.44%, outperforming the Hang Seng Index's growth of 24.14% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Huajian Medical [3] - The company's price-to-earnings (P/E) ratio is 33.12, ranking 37th in the healthcare equipment and services industry, which has an average P/E ratio of -0.3 and a median of 1.39 [3] - Comparatively, other companies in the industry have P/E ratios such as Jingjiu Kangliao at 0.38, Juxing Medical Holdings at 0.44, and Yihui Group at 2.35 [3]
华检医疗（01931.HK）8月6日收盘上涨38.43%，成交5761.21万港元